Journal article
A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer
Abstract
Purpose The objective of this trial was to evaluate the clinical effects of sorafenib, a multi-targeted kinase inhibitor, in combination with androgen receptor blockade in patients with castration-resistant prostate cancer. Methods This was a multicenter, two-stage, phase 2 trial. Eligible patients had rising PSA, minimal symptoms and were chemotherapy-naïve. Sorafenib 400 mg twice daily was administered with bicalutamide 50 mg once daily on a …
Authors
Beardsley EK; Hotte SJ; North S; Ellard SL; Winquist E; Kollmannsberger C; Mukherjee SD; Chi KN
Journal
Investigational New Drugs, Vol. 30, No. 4, pp. 1652–1659
Publisher
Springer Nature
Publication Date
August 2012
DOI
10.1007/s10637-011-9722-5
ISSN
0167-6997
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedAged, 80 and overAnilidesAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBenzenesulfonatesHumansKaplan-Meier EstimateMaleMiddle AgedNiacinamideNitrilesOrchiectomyPhenylurea CompoundsProstate-Specific AntigenProstatic NeoplasmsPyridinesSorafenibTime FactorsTosyl CompoundsTreatment Failure